Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Specialty Chemicals

Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India. The company operates in two segments, Chemicals and Hotel. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, acetonitrile, dimethylcarbonate, propylene glycol, and propylene carbonate. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, choline chloride, mono-ethyl amine hydrochloride, and benzyl tri ethyl ammonium chloride; and pharma excipients, such as poly vinyl pyrrolidone. In addition, it operates Balaji Sarovar Premiere, a hotel in Solapur, Maharashtra, as well as engages in the provision of hotel, restaurant, and hospitality services. The company serves pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning chemical, dye and textile, pesticides and insecticides, water treatment chemical, optical brighteners, corrosion inhabitations, cosmetics, explosives, and foundry chemicals industries. It also exports its products to the United States, the United Kingdom, Argentina, Latin America, Canada, Israel, Australia, Bangladesh, Germany, Italy, Egypt, South Africa, and internationally. Balaji Amines Limited was incorporated in 1988 and is headquartered in Solapur, India.

Revenue projections:

Revenue projections for BALAMINES
Revenue projections for BALAMINES

Investors are expected to be cautious with BALAMINES, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 16.831532
debtToEquity 1.530000
earningsGrowth -0.073000
revenueGrowth 0.059000
grossMargins 0.433780
operatingMargins 0.128280
trailingEps 44.430000
forwardEps 64.700000

BALAMINES's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
BALAMINES's low earnings and revenue growth highlight potential profit shrinkage. This suggests that the company may struggle to maintain its financial performance, raising concerns about its future profitability.
BALAMINES's negative gross and operating margins indicate that the company is unable to generate profit from its core business activities. This suggests financial strain and could be a sign of deeper cost management issues.
BALAMINES's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting BALAMINES to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for BALAMINES
Price projections for BALAMINES

Price projections for BALAMINES have been steadily revised downward over time, indicating growing concerns about the company's future performance. This downward trend reflects reduced optimism among analysts regarding BALAMINES's ability to meet previous expectations.

Recommendation changes over time:

Recommendations trend for BALAMINES
Recommendations trend for BALAMINES


BALAMINES has received no definitive buy or sell ratings from analysts, presenting a mixed outlook for the stock. This uncertainty could leave investors hesitant, prompting them to consider other market indicators before making any investment decisions.